论文部分内容阅读
目的观察瑞舒伐他汀对急性ST段抬高型心肌梗死患者溶栓治疗后血清炎症因子及预后的影响。方法选取2014年9月-2015年9月来医院进行治疗的急性ST段抬高型心肌梗死患者162例,随机分为对照组和治疗组各81例。给予2组患者冠心病Ⅱ级预防药物治疗,治疗组和对照组患者在此基础上分别采用瑞舒伐他汀20mg/d和5mg/d治疗,比较2组患者治疗效果。结果治疗4周后,治疗组LVESD、LVEDD及LVEF值与治疗前相比差异有统计学意义(P<0.05)。治疗4周后,2组患者的IL-6、TNF-α、NT-pro BNP及hs-CRP,明显低于治疗前(P<0.05)。治疗4周后,治疗组IL-6、TNF-α、NT-pro BNP及hs-CRP明显低于对照组,差异有统计学意义(P<0.05)。结论对急性ST段抬高型心肌梗死患者的炎性反应,瑞舒伐他汀治疗具有良好的作用。
Objective To observe the effect of rosuvastatin on serum inflammatory factors and prognosis after thrombolysis in patients with acute ST-segment elevation myocardial infarction. Methods A total of 162 acute ST-segment myocardial infarction patients who were hospitalized from September 2014 to September 2015 were randomly divided into control group and treatment group (n = 81). Patients in the treatment group and the control group were given rosuvastatin 20 mg / d and 5 mg / d respectively, and the treatment effect was compared between the two groups. Results After 4 weeks of treatment, the difference of LVESD, LVEDD and LVEF between the two groups was statistically significant (P <0.05). After 4 weeks of treatment, the levels of IL-6, TNF-α, NT-pro BNP and hs-CRP in two groups were significantly lower than those before treatment (P <0.05). After 4 weeks of treatment, the levels of IL-6, TNF-α, NT-pro BNP and hs-CRP in the treatment group were significantly lower than those in the control group (P <0.05). Conclusion The inflammatory response in patients with acute ST-elevation myocardial infarction, rosuvastatin treatment has a good effect.